Share on Facebook Share on Twitter Email
Answers.com

TRAIL

 
Wikipedia: TRAIL
edit
Tumor necrosis factor (ligand) superfamily, member 10
PDB rendering based on 1d0g.
Available structures: 1d0g, 1d2q, 1d4v, 1dg6, 1du3
Identifiers
Symbols TNFSF10; APO2L; Apo-2L; CD253; TL2; TRAIL
External IDs OMIM: 603598 MGI107414 HomoloGene2824
RNA expression pattern

More reference expression data

Orthologs
Human Mouse
Entrez 8743 22035
Ensembl ENSG00000121858 ENSMUSG00000039304
Uniprot P50591 Q3TZR6
Refseq NM_003810 (mRNA)
NP_003801 (protein)
NM_009425 (mRNA)
NP_033451 (protein)
Location Chr 3: 173.71 - 173.72 Mb Chr 3: 27.51 - 27.53 Mb
Pubmed search [1] [2]

In the field of cell biology, TNF-related apoptosis-inducing ligand (TRAIL), is a protein which functions as a ligand which induces the process of cell death called apoptosis. TRAIL has also been designated CD253 (cluster of differentiation 253).[1][2]

Contents

Gene

In humans, the gene that encodes for TRAIL is located at chromosome 3q26, which is not close to other TNF family members. The genomic structure of the TRAIL gene spans approximately 20 kb and is composed of five exonic segments 222, 138, 42, 106, and 1245 nucleotides and four introns of approximately 8.2, 3.2, 2.3 and 2.3 kb. The TRAIL gene lacks TATA and CAAT boxes and the promotor region contains putative response elements for GATA, AP-1, C/EBP, SP-1, OCT-1, AP3, PEA3, CF-1, and ISRE.

Structure

TRAIL shows homology to other members of the tumor necrosis factor superfamily. It is composed of 281 amino acids and has characteristics of a type II transmembrane protein (i.e. no leader sequence and an internal transmembrane domain). The N-terminal cytoplasmic domain is not conserved across family members, however, the C-terminal extracellular domain is conserved and can be proteolytically cleaved from the cell surface. TRAIL forms a homotrimer that binds three receptor molecules.

Function

TRAIL binds to the death receptors DR4 (TRAIL-RI) and DR5 (TRAIL-RII). The process of apoptosis is caspase-8-dependent. Caspase-8 activates downstream effector caspases including procaspase-3, -6, and -7, leading to activation of specific kinases.[3] TRAIL also binds the receptors DcR1 and DcR2, which do not contain a cytoplasmic domain (DcR1) or contain a truncated death domain (DcR2). DcR1 functions as a TRAIL-neutralizing decoy-receptor. The cytoplasmic domain of DcR2 is functional and activates NFkappaB. In cells expressing DcR2, TRAIL binding therefore activates NFkappaB, leading to transcription of genes known to antagonize the death signaling pathway and/or to promote inflammation.

Interactions

TRAIL has been shown to interact with TNFRSF10B.[4][5][6]

See also

References

  1. ^ Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA (December 1995). "Identification and characterization of a new member of the TNF family that induces apoptosis". Immunity 3 (6): 673–82. doi:10.1016/1074-7613(95)90057-8. PMID 8777713. 
  2. ^ Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (May 1996). "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family". J. Biol. Chem. 271 (22): 12687–90. doi:10.1074/jbc.271.22.12687. PMID 8663110. http://www.jbc.org/cgi/content/full/271/22/12687. 
  3. ^ Song JJ, Lee YJ (May 2008). "Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily". Cell. Signal. 20 (5): 892–906. doi:10.1016/j.cellsig.2008.01.001. PMID 18276109. 
  4. ^ Kaptein, A; Jansen M, Dilaver G, Kitson J, Dash L, Wang E, Owen M J, Bodmer J L, Tschopp J, Farrow S N (Nov. 2000). "Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3)". FEBS Lett. (NETHERLANDS) 485 (2-3): 135–41. doi:10.1016/S0014-5793(00)02219-5. ISSN 0014-5793. PMID 11094155. 
  5. ^ Walczak, H; Degli-Esposti M A, Johnson R S, Smolak P J, Waugh J Y, Boiani N, Timour M S, Gerhart M J, Schooley K A, Smith C A, Goodwin R G, Rauch C T (Sep. 1997). "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL". EMBO J. (ENGLAND) 16 (17): 5386–97. doi:10.1093/emboj/16.17.5386. ISSN 0261-4189. PMID 9311998. 
  6. ^ Hymowitz, S G; Christinger H W, Fuh G, Ultsch M, O'Connell M, Kelley R F, Ashkenazi A, de Vos A M (Oct. 1999). "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5". Mol. Cell (UNITED STATES) 4 (4): 563–71. doi:10.1016/S1097-2765(00)80207-5. ISSN 1097-2765. PMID 10549288. 

Further reading

  • Wiley S, Schooley K, Smolak P, Din W, Huang C, Nicholl J, Sutherland G, Smith T, Rauch C, Smith C (1995). "Identification and characterization of a new member of the TNF family that induces apoptosis". Immunity 3 (6): 673–82. doi:10.1016/1074-7613(95)90057-8. PMID 8777713. 
  • Almasan A, Ashkenazi A (2004). "Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy.". Cytokine Growth Factor Rev. 14 (3-4): 337–48. doi:10.1016/S1359-6101(03)00029-7. PMID 12787570. 
  • Cha SS, Song YL, Oh BH (2004). "Specificity of molecular recognition learned from the crystal structures of TRAIL and the TRAIL:sDR5 complex.". Vitam. Horm. 67: 1–17. doi:10.1016/S0083-6729(04)67001-4. PMID 15110168. 
  • Song C, Jin B (2005). "TRAIL (CD253), a new member of the TNF superfamily.". J. Biol. Regul. Homeost. Agents 19 (1-2): 73–7. PMID 16178278. 
  • Bucur O, Ray S, Bucur MC, Almasan A (2006). "APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy.". Front. Biosci. 11: 1549–68. doi:10.2741/1903. PMID 16368536. 

External links


Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics
 
 

 

Copyrights:

Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "TRAIL" Read more